Trial
NCT02994953
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Advanced Solid Tumors
Intervention
Avelumab
Why stopped
The study was terminated due to pre-specified futility criteria met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-20